Trial Reporting in Immuno-Oncology (TRIO): an American society of clinical oncology-society for immunotherapy of cancer statement

• Published in: Journal for immunotherapy of cancer Vol. 6; no. 1; pp. 108 - 10
• Main Authors: Tsimberidou, Apostolia M, Levit, Laura A, Schilsky, Richard L, Averbuch, Steven D, Chen, Daniel, Kirkwood, John M, McShane, Lisa M, Sharon, Elad, Mileham, Kathryn F, Postow, Michael A
• Format: Journal Article
• Language: English
• Published: England BioMed Central Ltd 19-10-2018; BMJ Publishing Group LTD; BioMed Central; BMJ Publishing Group
• Subjects: Analysis; Biomarkers; Cancer; Cancer therapies; Cancer treatment; Cell death; Chemotherapy; Clinical trials; Cytokines; Data collection; FDA approval; Hypotheses; Immunotherapy; Licensing, certification and accreditation; Medical research; Oncology; Position and Guidelines; Tumors; Working groups; United States
• ISSN: 2051-1426; 2051-1426
• DOI: 10.1186/s40425-018-0426-7

To develop recommendations for clinical trial reporting that address the unique efficacy, toxicity, and combination and sequencing aspects of immuno-oncology (IO) treatments.
ASCO and the Society for Immunotherapy of Cancer (SITC) convened a working group that consisted of practicing medical oncologists, immunologists, clinical researchers, biostatisticians, and representatives from industry and government to develop Trial Reporting in Immuno-Oncology (TRIO) recommendations. These recommendations are based on expert consensus, given that existing data to support evidence-based recommendations are limited.
The TRIO recommendations are intended to improve the reporting of IO clinical trials and thus provide more complete evidence on the relative benefits and risks of an IO therapeutic approach. Given the rapid expansion of the number of IO clinical trials and ongoing improvements to the evidence base supporting the use of IO treatments in clinical care, these recommendations will likely need regular revision as the IO field develops.